Modality
Multispecific
MOA
CDK4/6i
Target
FLT3
Pathway
STING
Cervical CaCTCLEoE
Development Pipeline
Preclinical
~Jan 2012
→ ~Apr 2013
Phase 1
~Jul 2013
→ ~Oct 2014
Phase 2
~Jan 2015
→ ~Apr 2016
Phase 3
~Jul 2016
→ ~Oct 2017
NDA/BLA
~Jan 2018
→ ~Apr 2019
Approved
Jul 2019
→ Sep 2030
ApprovedCurrent
NCT07307171
896 pts·Cervical Ca
2022-05→TBD·Not yet recruiting
NCT04151919
2,339 pts·EoE
2019-07→2030-09·Not yet recruiting
3,235 total pts2 indications
CompletedCurrentUpcoming
Catalysts (1)
2030-09-234.5y awayPh3 Readout· EoE
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Not yet…
Approved
Not yet…
Catalysts
Ph3 Readout
2030-09-23 · 4.5y away
EoE
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07307171 | Approved | Cervical Ca | Not yet recr... | 896 | SRI-4 |
| NCT04151919 | Approved | EoE | Not yet recr... | 2339 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |